CDW Holding (SG:BXE) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
CDW Holding Limited is making significant progress in its biotechnology division by enhancing antibody research aimed at specific cancers. Their efforts focus on improving antibody affinity, with plans to complete an antibody library by the end of 2025, paving the way for more efficient antibody acquisition. This initiative is part of CDW’s strategy to diversify and tap into the promising life sciences market.
For further insights into SG:BXE stock, check out TipRanks’ Stock Analysis page.